Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma reported a decrease in its H1 earnings per share from $0.04 to $(0.00) year-over-year, and a decline in sales from $5.39 million to $2.57 million.
August 29, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Redhill Biopharma's H1 earnings per share fell to $(0.00) from $0.04, and sales decreased to $2.57 million from $5.39 million year-over-year.
The significant drop in both EPS and sales indicates a decline in financial performance, which is likely to negatively impact investor sentiment and put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100